Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: The Relation of GnRH Treatment to QTc Interval in Transgender Female Youth: A Time Series Study
Brief Summary:
Background: The QT interval of the electrocardiogram (ECG), corrected for heart rate (QTc), is a measure of the duration of ventricular repolarization and is a widely used marker of ventricular arrhythmia risk. Testosterone has a shortening effect on QTc length, and the QTc interval in males is shorter than in females after the onset of puberty. Transgender female adolescents are treated with GnRH agonists or spironolactone that suppress endogenous testosterone secretion and might increase the QT interval sufficiently to increase the risk for malignant ventricular arrhythmias. There are no current guidelines regarding monitoring QTc interval in transgender females undergoing GnRH agonist treatment.
Objective: To assess the effect of GnRH agonist treatment on QTc interval in transfemale youth.
Methods: A quasi-experimental time series study of transgender female adolescent, seen at UCSF Child and Adolescent Gender Center (CAGC) during 2017-2019.
Specific aims:
To assess the impact of GnRH agonist treatment on QTc interval length in transgender female adolescent